Home
Transactions

Work Area: Transactions

BlackBerry will re-start monetisation of remaining patents if sale closes this quarter

CEO John Chen says company will use a third party to extract value from 2,000 patents it is keeping

The European Commission’s SEP licensing plans are terrible on every level

Reported DG Grow proposals designed to make FRAND dealmaking in Europe more transparent, predictable and efficient are one-sided and poorly thought-through, so will do much more harm than good

Janssen’s latest move against Amgen highlights shifting pharma patent strategies

J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition

Latest content

Five key patent transactions takeaways

An over-arching theme during an IAM event was the key importance of relationships, trust and empathy between parties when deals are getting done

11 November 2022

WiLAN revenues plummet in Q3 on prior year but Micron deal excluded

Strategic review of the licensing business nears a year in motion with no news on potential divestment announced

10 November 2022

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

04 November 2022

France Brevets’ public sector links hindered monetisation efforts, says CEO

As the sovereign patent fund closes down, CEO Didier Patry shares his thoughts with IAM readers on the organisation’s work over the past decade

03 November 2022

IP finance, monetisation and much more take centre stage on Day One of IPBC Asia 2022

A broad range of subjects and talking points - including a plenary address from JPO Commissioner Koichi Hamano - kept the 400+ delegates engaged as the event got underway in Tokyo

01 November 2022

BlackBerry has ‘lost the signal’ … again

The series of missteps and errors in the Canadian company’s struggling patent portfolio sale offers a cautionary tale to any IP owner emulating this in future

29 October 2022

Myovant $2.9 billion buyout is the product of smart IP deal-making

The company’s high value was produced by a series of innovative patent transactions

27 October 2022

Trademarks and brands: key considerations for M&A transactions

It is crucial that a buyer or seller of a company does not overlook trademarks and brands in business acquisitions, or any red flags in that area. Luckily, there are solutions to overcome such complexities.

26 October 2022

US patent allowance crucial to $566 million Aveo Oncology buyout

Success at the USPTO clinched a premium-price acquisition for the oncology innovator

25 October 2022

Drug royalty sales supercharged by sinking biotech valuations, says leading dealmaker

Following the firm’s recent $115 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband says a flurry of activity is underway in the market

03 October 2022

Unlock unlimited access to all IAM content